Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 24, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on June 23, 2025, as part of an existing buyback programme.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (June 23, 2025): 483,823 ordinary shares
- Volume-Weighted Average Price: 1,403.43 GBp
- Price Range: 1,398.00 GBp (Low) to 1,414.50 GBp (High)
- Trading Venue: London Stock Exchange (XLON)
- Broker: Merrill Lynch International
- Treasury Shares Held: 223,761,425 (post-transaction)
- Shares in Issue (excluding Treasury): 4,091,584,047
- Treasury Voting Rights Percentage: 5.47%
Material Changes
Since the commencement of the current non-discretionary agreement on June 4, 2025, GSK has purchased an aggregate of 5,627,042 ordinary shares. The transaction reported herein represents the latest activity under this programme.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or management commentary regarding business performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the current buyback programme.
- Confirm the impact of the 5.47% treasury share holding on voting rights calculations for major shareholders.
- Review the Q1 2025 Results and 2024 Form 20-F for context on the company's overall liquidity and capital structure.